Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease

Annals of Hepatology

卷:19

Yujen Tseng¹  Jie Liu²  Ge Ge³  Yanyun Ma⁴  Hao Ding⁴  Jun Zhang⁵ 

[1] China Medical University, Shenyang, China;

[2] Six-sector Industrial Research Institute, Fudan University, Shanghai, 200433, China;

[3] Department of Dermatology, Air Force Medical Center, Beijing, China;

[4] Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China;

[5] Human Phenome Institute, Fudan University, Shanghai, 201203, China;

关键词: Fatty liver;    Autophagy;    mTORC1;    Steatosis;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction and objectives: Autophagy has emerged as a critical regulatory pathway in non-alcoholic fatty liver disease (NAFLD). However, the variability of hepatic autophagy during NAFLD development remains controversial. This study aimed to elucidate the dynamics of hepatic autophagy and its underlying mechanism during NAFLD development both in vivo and in vitro. Materials and methods: Autophagy markers were evaluated in the livers of mice fed a high fat diet or a methionine-choline-deficient diet and in HepG2 cells treated with palmitic acid (PA) by western blotting. Intrahepatic and intracellular triacylglycerol levels were assessed using biochemical quantification and lipid staining. Autophagic flux was monitored using an LC3 turnover assay and tandem mRFP-GFP-LC3 fluorescence analysis. Results: Hepatic autophagy was enhanced in early stages but blocked at later stages of NAFLD development both in vivo and in vitro. Analysis of autophagic flux revealed that both autophagic synthesis and degradation were initially activated and progressively inhibited afterwards. The activation of mammalian target of rapamycin complex 1 (mTORC1), a central regulator of autophagy, was found to be negatively correlated with autophagic synthesis; moreover, pharmacological inhibition of mTORC1 by rapamycin alleviated hepatic steatosis through recovery of autophagic flux in hepatocytes with prolonged PA treatment. Conclusions: Hepatic autophagy fluctuates during the development of NAFLD in which mTORC1 signalling plays a critical regulatory role, suggesting a therapeutic potential of autophagy modulation by targeting the mTORC1 signalling pathway in NAFLD.

【 授权许可】

Unknown